phase for retinopathy. 4 According to this calculation, the average duration of the asymptomatic phase for retinopathy was approximately 4-7 years. Because this estimate did not take the passage of time before asymptomatic retinopathy into consideration, Harris et al. further estimated the duration from impaired glucose tolerance (IGT) to symptomatic retinopathy as 9-12 years. Harris et al. based their work on a study by Jarrett, which indicated that the time to the occurrence of retinopathy without any symptoms of NIDDM for patients with IGT was around 5 years. 5 However, such an estimate might be unreliable because the estimation was not based on empirical follow-up data.
In order to estimate MST, it is typical to detect asymptomatic cases via community-based NIDDM screening. Symptomatic cases may be found by vigorous follow-up of individuals in the screening programme or from a registry system of previous estimates of MST for other chronic diseases such as cancer. 6 One then estimates the progression rate from the asymptomatic phase to symptomatic phase on the basis of two observational modes. However, in Taiwan, it is difficult to identify symptomatic cases due, in part, to the lack of a registry system for NIDDM, and partly due to the attribution problem in community-based follow-up study. Furthermore, because there is no registry system for NIDDM in Taiwan, an estimate of the incidence of NIDDM is not readily available.
The assessment of the efficacy of a screening programme is usually based on a primary endpoint such as death from NIDDM. It is worthwhile comparing the hazard rate of death from NIDDM between asymptomatic and symptomatic cases. The best way to evaluate the efficacy of NIDDM screening is based on a population-based randomized trial. However, cost and ethical issues preclude this. In addition, although a randomized trial can show whether screening works, it is not able to show why and how screening achieves benefit. Having a clear understanding of the disease's natural history helps determine the optimal screening interval without relying on the evaluation of a randomized trial. For example, a short MST might suggest an intensive screening programme and vice versa.
To take the above problems into consideration, a discrete Markov chain model is proposed to construct the disease's natural history from the disease-free state through the asymptomatic phase, symptomatic phase and finally to death from NIDDM. Transition rates between states can be estimated. One can apply these parameters to predict the effect of screening frequencies on deaths from NIDDM.
The purposes of this study are to apply Markov chain models to: (1) estimate the baseline incidence and the progression rate from the asymptomatic phase to the symptomatic phase, i.e. the mean sojourn time (MST) for NIDDM; (2) estimate death rates from the asymptomatic and symptomatic phases to death from NIDDM, taking other competing causes of deaths into account; (3) predict the effect of different screening frequencies on deaths from NIDDM based on (1) and (2); and (4) make a tentative suggestion for NIDDM screening in Taiwan based on (1) through (3).
Methods

Data resource
Data used in this study are from a community-based NIDDM screening project in Puli County, located in central Taiwan. Details of the study design and some descriptive results have been published elsewhere. 2 In brief, there were three rounds of screening carried out from July 1987 to February 1988, July 1991 to February 1992, and July 1994 to February 1995. The screening method was based on fasting and oral glucose tolerance test (OGTT). Because this is a non-randomized service, new subjects may enter the programme for first screening at any of the three rounds. Thus, three fixed cohorts were defined (1987-1988, 1991-1992 and 1994-1995) according to when subjects were invited to attend their first screen. It should be noted that because so few subjects attended the screen between July 1994 and February 1995, we excluded them from the analysis. Accordingly, only two fixed cohorts, 1987-1988 (1152 subjects) and 1991-1992 (1314 subjects), were used for estimation of parameters in this study. Figure 1 shows number of participants and results of screening for two fixed cohorts.
Among two fixed cohorts there were 331 subjects in the first cohort and 806 subjects in the second cohort at first screen with fasting plasma glucose (FPG) levels between 5.6 and 7.8 mM but for whom FPG and 2-h plasma glucose of OGTT was unknown because they did not take the OGTT test. As we could not ascertain the status of NIDDM for these subjects we excluded them from analysis. Moreover, there were 110 subjects who were reported as previously having NIDDM by questionnaire (77 and 33 cases in 1987-1988 cohort and 1991-1992 cohort, Figure 1 A diagram for results of NIDDM screening for two fixed cohorts (1987-1988 and 1991-1992) , NIDDM screening in Puli, Taiwan respectively). By definition, these cases were classified as symptomatic cases. However, these subjects were excluded from the analysis because we were not sure whether they were representative of clinical NIDDM for the underlying population. Some subjects with clinical NIDDM might stay in hospital rather than at home, and the information on some of these subjects might not have been reliable due to the self-reporting nature of the questionnaire. The age of subjects in both cohorts was over 30 years. Because there were only four subjects over 80, the analysis is limited to those р80 years old (Figure 1 ).
After these exclusions, only 742 (677 + 65) in the 1987-1988 cohort and 473 (434 + 39) in the1991-1992 cohort remained for analysis based on the Markov chain models (see below). Among the subjects, 104 (65 and 39 in each cohort, respectively) were identified as positive for NIDDM at first screening. Of the 677 subjects detected as negative for NIDDM at the first screening, only 237 attended the second screening, and 10 were found to be positive. Because this was a community-based screening project, the 114 positive subjects detected were defined as being in the asymptomatic phase of NIDDM.
In order to obtain information on the causes of death for these asymptomatic subjects, a total of 1215 subjects were linked to a mortality registry between 1987 and 1994. Of the 114 asymptomatic subjects with NIDDM (104 at the first screening [including 1987-1988 and 1991-1992 cohorts] and 10 at the second screening), there were eight deaths from NIDDM (ICD: 250) and 11 deaths from other causes. Of 1111 normal subjects, there were 50 other causes of deaths, from a variety of causes. Table 1 summarizes the results of screening by detection modes and identification of deaths from mortality registry for two fixed cohorts.
Statistical methods
The natural history of NIDDM was constructed as follows: There are several assumptions made in this model to estimate parameters. Firstly, we assume the above disease process is progressive, i.e. there is no regression from the symptomatic to the asymptomatic phase. We believe this assumption does not depart from empirical data because it seems unlikely for subjects diagnosed as diabetes mellitus to revert to normal without any treatment. In addition, there is no possibility of regression from symptomatic NIDDM to asymptomatic NIDDM. Secondly, for simplification, we assume the hazard rates of other causes of death for asymptomatic cases are identical to that for symptomatic cases, i.e. µ 2 = µ 3 . This assumption is, however, not unreasonable because the major difference between asymptomatic and symptomatic NIDDM is the risk for deaths from NIDDM rather than other causes of deaths.
There are three reasons to account for why a Markov chain model, rather than the traditional survival analysis such as accelerated failure time model, is required to estimate parameters. Firstly, as the traditional survival analysis estimate hazard rate merely based on two states it is difficult for such a simple model 
First screen
Asymptomatic NIDDM (0→1, age at first screen (age)) 104 P 01 (age)/P 00 (age) + P 01 (age)
Disease free (0→0, age at first screen (age)) 1111 P 00 (age)/P 00 (age) + P 01 (age)
Second screen
Asymptomatic NIDDM (0→1, 4 years (screening interval)) 10 P 01 (screening interval)
Disease free (0→0, 4 years (screening interval)) 227 P 00 (screening interval)
Deaths
Deaths from NIDDM (1→3, time to death) 8 dP 12 (time to death)
Other causes of death (0→4, time to death) 50 dP 00 (time to death)
Other causes of death (1→4, time to death) 11 dP 11 (time to death) to deal with multi-state disease process as in five-state Markov illness-and-death model. Secondly, the transition from the asymptomatic phase to the symptomatic phase is hidden because the natural history would be interrupted if asymptomatic NIDDM cases were detected and treated. This leads to direct estimation of the transition rate of λ 3 with great difficulty. Thirdly, because it is also difficult to ascertain symptomatic cases due to the lack of a registry or incomplete follow-up, no symptomatic cases were used in the estimation. To overcome these problems, a Markov chain model was therefore proposed to indirectly estimate hazard rates from asymptomatic NIDDM to symptomatic NIDDM and from symptomatic NIDDM to deaths from NIDDM based on transition modes (0→1) and (1→3) though we do not have observed symptomatic NIDDM cases (state 2). This is similar to phase-type distribution widely used in stochastic process. 12 In addition, transition modes including (1→4) and (0→4) are used to estimate the hazard rates of competing causes of deaths, i.e. µ 1 , µ 2 and µ 3 . Data required for estimating the above parameters are listed in Table 1 . These include disease free, asymptomatic NIDDM detected at screens, deaths from NIDDM and deaths from other causes of deaths ascertained from mortality registry. Information provided for parameter estimation include age at first screen, screening interval and time to death. This is available from screening results for two fixed cohorts and mortality registry in Taiwan. Although a five-state Markov illness-and-death model is complicated and has many parameters it might be sufficient to estimate five parameters based on seven transition modes observed in this study ( Table 1) .
The derivation of the total likelihood functions is shown in the Appendix. The estimation procedure was based on the SAS NLIN procedure, 13 similar to the work of Duffy et al. 7 To estimate the effect of inter-screening interval on the efficacy of screening a simulation programme based on estimated results was implemented. It should be noted that using simulation to estimate the effect of screening frequencies can dispense with the use of randomized trial to demonstrate the efficacy of screening which might be costly and infeasible. The stop-split design is employed in this simulation. 14 Suppose a hypothetical population with size of 40 000 subjects aged у30 years is randomly assigned to four arms: annual screening, biennial screening, 4-yearly screening and a control group for 8 years. Because the study design is based on the stop-split design seven, four and two rounds of screening were offered to subjects in the annual, biennial and 4-yearly screening groups, respectively, during the study period. The control group has one round of screening at the close of the trial. We also assume 100% attendance in this simulation. We use parameters estimated from the above Markov chain model as the base case estimates (assuming the best estimates) to calculate the simulated results. We also performed a sensitivity analysis to estimate the uncertainty of the simulated results by applying the upper and lower 95% confidence interval (CI) to calculating the upper and lower ranges of the simulated results. Table 2 shows the results for the above five-state Markov illness-and death model. The annual incidence of asymptomatic NIDDM is 10.67 (95% CI : 8.26-13.79) per 1000. The progression rate from the asymptomatic to the symptomatic phase is 0.12 (95% CI : 0.09-0.17). The inversion of λ 2 gives an estimated 8 (95% CI : 5.74-11.29) years of MST. A long MST suggests that it is worthwhile to detect NIDDM at an early stage. The annual hazard rate of dying from NIDDM for symptomatic NIDDM is 2.27%. This implies there is a high risk of dying from NIDDM for subjects with symptomatic NIDDM.
Results
Markov illness-and-death model
The application of these parameters to the transition probabilities in 10 years yields the following matrix: Similarly, the cumulative 10-year survival rate for symptomatic NIDDM is P 22 (10) = 69.45%
The relative 10-year survival rate for symptomatic NIDDM versus asymptomatic NIDDM is 0.88.
Prediction of deaths from NIDDM by different screening frequencies
The application of the parameters in Table 2 to different screening regimens gives the following transition probability matrix: 

It should be noted that the likelihood hazard rate of death from NIDDM for asymptomatic NIDDM is almost triple when the screening interval is changed from 4 years (4-yearly screening regime) to 8 years (control group).
We applied the above transition probability matrix to the corresponding screening regimens to calculate the predicted asympotmatic NIDDM, symptomatic NIDDM, deaths from NIDDM and deaths from other causes. The procedure for calculating the predicted outcome was illustrated with the 4-yearly screening regime versus the control group. The definition of transition probabilities used in the following illustration refers to the equation (A-1) in the Appendix. Thus, P 01 (age) is denoted as the probability of being asymptomatic NIDDM from birth to age at first screen. P 01 (4), P 02 (4), P 03 (4) and P 04 (4) are denoted as the probability of transitions from normal to asymptomatic NIDDM (state 1), to symptomatic NIDDM (state 2), to deaths from NIDDM (state 3) and to other causes of deaths (state 4) respectively during 4-year inter-screening interval. Likewise, P 23 (10) and P 13 (10) are the10-year risk of being dead from NIDDM for asymptomatic (state 1) and symptomatic NIDDM (state 2). According to the above definition, the predicted numbers of asymptomatic and symptomatic NIDDM and deaths from NIDDM are calculated as follows (a) Disease free → Asymptomatic NIDDM (first screen) P 01 (age) S 1 = 10 000 × = 777.37 P 00 (age) + P 01 (age) age: age at first screen The predicted relative mortality for the 4-yearly screening regimen versus the control group has an RR = 0.60 (95 CI : 0.49 -0.74). This means that there is a 40% reduction of deaths from NIDDM attributed to blood sugar screening. A similar calculation is applied to the biennial screening regimen versus the control group. Table 3 shows predicted deaths from NIDDM for asymptomatic and symptomatic NIDDM by annual, biennial, and 4-yearly regimens and the control group. The more intensive the screening regimen, the more reduction of symptomatic NIDDM and deaths from NIDDM. However, there was no substantial difference among the annual, biennial and 4-yearly screening regimens.
Results of a sensitivity analysis using 95% CI obtained from Table 2 show the upper and lower ranges of mortality reduction due to a 4-yearly screening regime are 49% (95% CI : 23-66%) and 26% (95% CI : 16-34%) respectively.
Model diagnostics
To verify the adequacy of the model, observed and fitted values were compared using various transition modes, as shown in Table 4 . The fitted values are very close to the observed values. The goodness of fit (χ 2 (2) = 2.16, P = 0.34) suggests that a fivestate Markov illness-and death model is adequate.
Discussion
According to the five-state Markov illness-and-death model, we predict that there should be a 40% (95% CI : 26-51%) mortality reduction from NIDDM as a result of 4-yearly screening for NIDDM. Results from a sensitivity analysis also show there is at least 26% mortality reduction from NIDDM due to 4-yearly screening. The estimated 8-year MST is close to the 9-12 years estimated by Harris et al. 4 Such a long MST warrants screening for NIDDM in order to obtain the earliest diagnosis possible.
There are several concerns for estimated results in this study. First of all, the major caveat in this study is that over half the subjects were excluded from analysis due to refusing to attend the second screen (1987-1988 cohort) or to take the OGTT test. It is, however, difficult to incorporate these subjects into the model since we can not ascertain their NIDDM status. It is also difficult to contemplate on how exclusion of these subjects from analysis will affect the estimated results. If those who refused the OGTT have a more rapid progression from asymptomatic NIDDM to symptomatic NIDDM than the participants the MST might be overestimated. Conversely, if the progression rate in refusers is slower than that in attendees the MST is underestimated. If the latter is true more benefit would be expected for NIDDM screening due to a longer sojourn time. As regards the former situation, to what extent they will affect the efficacy of NIDDM screening is strongly dependent on how the estimate of MST is overestimated. However, it seems unlikely to be largely overestimated in this study for two reasons. Firstly, the result is consistent with that estimated in Harris et al. 4 Secondly, as there are more missing in the 1991-1992 cohort we reestimated parameters after excluding subjects in the 1991-1992 cohort to examine whether there was a substantial change in the estimates: results in Table 5 show they were very similar to those obtained from Table 2 .
The second one is related to excluding 110 subjects who were reported as previously having NIDDM from analysis due to incomplete identification as explained in Methods. It could be argued that exclusion of subjects might bias the results. However, we believe such bias could be reduced by applying conditional probability to the first screen (Table 1) as done in this study. This means we only model the results at first screen conditional on subjects with disease-free and asymptomatic NIDDM. This is the so-called left-truncated approach widely used in modelling the natural history of AIDS. 15 Thirdly, the primary endpoint for NIDDM screening, based on deaths from NIDDM, is insufficient because previous research has shown that at least 34-50% of deaths are explained by cardiovascular disease (CVD) compared to 10-24% by NIDDM. 16, 17 This suggests that in the evaluation of the efficacy of NIDDM screening, the primary endpoint should include deaths from CVD as well as NIDDM. This is why the hazard rate of death from other causes for asymptomatic or symptomatic NIDDM is much higher than that for normal subjects (Table 2 ). It should be noted that we could not estimate the effect of screening on the reduction in deaths from NIDDM and deaths from CVD separately because it is difficult to distinguish the cause of CVD as either due to NIDDM or from other causes of CVD unrelated to NIDDM and also the degrees of freedom to estimate parameters are insufficient. Consequently we put CVD into other causes of death and assume that the hazard rate of other causes of death for asymptomatic NIDDM is identical to that for symptomatic NIDDM. We think such an assumption is not unreasonable and leads to a conservative estimate of NIDDM screening benefits if deaths from CVD are significantly reduced in asymptomatic NIDDM. Further research should be done to clarify this issue.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Fourthly, although the relative survival shows that asymptomatic NIDDM has a more favourable survival than symptomatic NIDDM, great caution should be paid to the lead time and length bias in the theoretical aspect of screening. To adjust for lead-time bias, we first estimated the MST based on a threestate Markov chain model. We then applied the method of Walter and Sitt 18 to calculate the adjusted hazard rate, θ, based on the estimated MST and the observed life-table for asymptomatic NIDDM. According to this method, θ was estimated as 0.016182. Using this figure, post-lead-time survival was plotted against the Kaplan-Meier curve and the predicted symptomatic NIDDM survival curve (Figure 2 ). Since Figure 2 shows that there is no substantial difference between Kaplan-Meier and post-lead-time survival the benefit of NIDDM screening is unlikely to be accounted for by lead-time bias.
To examine the estimate for length bias, we excluded the first screening data (length bias usually occurs with the first screening) to re-estimate corresponding parameters as in Table 2 . There is no substantial difference between both results including and excluding first screen (data not shown).
Finally, as regards screening frequencies with respect to cost, a 4-yearly screening regimen is sufficient to achieve the maximum reduction in NIDDM mortality, given a fixed cost, after examining the effect of screening frequencies on deaths from NIDDM. There are no significant gains for annual and biennial screening regimens, as shown in Table 3 .
Two extensions for the proposed five-state Markov chain model could be made in future studies. Firstly, the proposed five-state Markov chain model could be extended to model the efficacy of treatment on NIDDM. However, since the primary interest in this study is the efficacy of screening rather than the efficacy of treatment we did not collect information on treatment. Ongoing research might be required to investigate this subject.
Secondly, since data used in this study is a community-based based screening project for Puli, a rural area in central Taiwan, inference made from this study may not be applicable to other urban communities because the different lifestyles of rural and urban communities might lead to different natural histories for NIDDM. However, our proposed Markov chain model could be applied to evaluate the efficacy of NIDDM screening for other similar NIDDM screening projects in Taiwan.
In conclusion, our study predicts the efficacy of an NIDDM screening consisting of a community-based repeated blood sugar survey. Modelling the natural history of NIDDM shows a long MST, which justifies the feasibility of early diagnosis of NIDDM. The results imply that a 4-yearly screening regimen for the high prevalence of NIDDM in Taiwan is necessary. The proposed five-state Markov chain model can be applied to other similar NIDDM screening projects. 
Transition probabilities
Likelihood function
According to the transition probabilities (A-1) and Table 1 , the total likelihood function is as follows:
(A-2)
age: age at the first screening t: time to death x: screening interval dP 00 (t), dP 11 (t), dP 12 (t) are the derivatives of P 00 (t), P 11 (t) and P 12 (t) respectively.
The component (A-2) can be decomposed into the following: the first and second components are likelihood for asymptomatic NIDDM and disease free at first screen. It should be noted that because symptomatic NIDDM subjects were excluded from the analysis, conditional probabilities were required in the above calculation. The third and fourth components are likelihoods for the disease-free and asymptomatic NIDDM at the second screening. The fifth and sixth components are likelihoods of death from NIDDM and other causes of death for asymptomatic NIDDM. The final component is the likelihood of death from other causes for disease-free subjects. Because the time to death is precisely known, an instantaneous density function should be used in the estimation.
To estimate maximum likelihood estimate (MLE) and variance of parameters, the first and second derivative are derived as follows:
= U(θ ) = 0 (A-3) θ = (λ 1 , λ 2 , λ 3 , µ 1 , µ 2 ,)′ = U′(θ )0 (A-4) U(θ) is the score function.
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